Qualigen Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(13,760,250) | $(21,034,643) |
| Loss from discontinued operations, net of tax | (1,285,240) | (7,140,181) |
| Loss from continuing operations | (12,475,010) | (13,894,462) |
| Adjustments to reconcile loss from continuing operations to net cash used in operating activities: | ||
| Depreciation and amortization | 4,495 | 12,165 |
| Stock-based compensation | 1,098,533 | 4,765,276 |
| Change in fair value of warrant liabilities | (2,035,469) | (906,345) |
| Loss on voluntary conversion of convertible debt | 1,077,287 | — |
| Accretion of discount on convertible debt | 1,469,640 | — |
| Loss on debt extinguishment | 625,653 | — |
| Loss on disposal of fixed assets | 21,747 | — |
| Fair value of warrant modification for professional services | 7,945 | 67,370 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (264,741) | (126,985) |
| Accounts payable | 1,603,422 | (43,440) |
| Accrued expenses and other current liabilities | (227,101) | (472,441) |
| Net cash used in operating activities - continuing operations | (9,093,599) | (10,598,862) |
| Net cash provided by (used in) operating activities - discontinued operations | (1,210,664) | (2,648,679) |
| Net cash used in operating activities | (10,304,263) | (13,247,541) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Net cash provided by (used in) investing activities - discontinued operations | 4,215,943 | (183,763) |
| Net cash provided by (used in) investing activities | 4,215,943 | (183,763) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Net proceeds from warrant exercises | — | 7,173 |
| Proceeds from issuance of convertible debt | — | 2,903,847 |
| Payments on convertible notes payable | (550,000) | — |
| Fractional share payments related to the reverse stock split | — | (505) |
| Net cash (used in)/provided by financing activities - continuing operations | (550,000) | 2,910,515 |
| Net cash used in financing activities - discontinued operations | — | — |
| Net cash (used in) provided by financing activities | (550,000) | 2,910,515 |
| Net change in cash and restricted cash | (6,638,320) | (10,520,789) |
| Effect of exchange rate changes on cash and restricted cash | — | 22,639 |
| Cash and restricted cash from continuing operations - beginning of period | 3,165,985 | 9,174,383 |
| Cash and restricted cash from discontinued operations - beginning of period | 3,874,138 | 8,363,890 |
| Less: cash and restricted cash from discontinued operations - end of period | — | (3,874,138) |
| Cash from continuing operations - end of period | $401,803 | $3,165,985 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid during the year for: | ||
| Interest | $— | $— |
| Taxes | $5,571 | $5,571 |
| NONCASH FINANCING AND INVESTING ACTIVITIES: | ||
| Net transfers to equipment held for lease from inventory | $83,281 | $— |
| Fair value of warrant liabilities on date of exercise | $— | $858 |
| Redemption of convertible debt into common stock | $254,316 | $— |
| Voluntary conversion of convertible debt into common stock | $1,112,582 | $— |
| Fair value of warrant modifications pursuant to Securities Purchase Agreement | $— | $9,439 |
| Fair value of warrant modifications for business acquisition | $— | $33,543 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.